Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amlitelimab Long-term Extension Study in Moderate to Severe Atopic Dermatitis (RIVER-AD)
NCT05492578Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2022
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
Phase 3, open-label trial of amlitelimab in atopic dermatitis (AD) (2 arms), sponsored by Sanofi. Primary endpoint: Treatment-Emergent Adverse Events at Week 332. Started Aug 2022; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05492578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492578.